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Non-alcoholic fatty liver disease (NAFLD) is an emerging global health problem and a
potential risk factor for type 2 diabetes, cardiovascular disease, and chronic kidney
disease. Nonalcoholic steatohepatitis (NASH), an advanced form of NAFLD, is a
predisposing factor for development of cirrhosis and hepatocellular carcinoma. The
increasing prevalence of NASH emphasizes the need for novel therapeutic approaches.
Although therapeutic drugs against NASH are not yet available, fundamental insights
into the pathogenesis of NASH have been made during the past few decades.
Multiple therapeutic strategies have been developed and are currently being explored
in clinical trials or preclinical testing. The pathogenesis of NASH involves multiple
intracellular/extracellular events in various cell types in the liver or crosstalk events
between the liver and other organs. Here, we review current findings and knowledge
regarding the pathogenesis of NASH, focusing on the most recent advances. We also
highlight hormone-based therapeutic approaches for treatment of NASH.
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INTRODUCTION
The liver is a central metabolic organ that coordinates whole-body energy homeostasis by
regulating glucose, lipid, and protein metabolism. The liver is also the main organ of detoxification
and processes pharmaceutical products or environmental xenobiotics absorbed from the intestine.
Therefore, liver diseases can cause systemic metabolic abnormalities; conversely, the liver is an
important target organ of diverse metabolic disorders, which may lead to the development of
non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease (AFLD), cirrhosis, and
hepatocellular carcinoma (HCC). Among these diseases, NAFLD is one of the most prevalent
chronic liver diseases and is an emerging global public health threat. NAFLD affects about
1.8 billion people worldwide with a prevalence of ∼20–30% (1). The pathological spectrum of
NAFLD ranges from simple steatosis to advanced stages including non-alcoholic steatohepatitis
(NASH), hepatic fibrosis, and cirrhosis. The prevalence of simple steatosis with lipid accumulation
exceeding 5% of liver weight ranges from 15 to 40% in the general population. Among
patients with simple steatosis, 10–20% develop NASH which is defined as steatosis with hepatic
inflammation and fibrosis (1). NASH can progress to more severe stages such as cirrhosis
and HCC (2). NAFLD/NASH is an emerging risk factor for type 2 diabetes, cardiovascular
disease, and chronic kidney disease (3). In particular, NAFLD/NASH is closely associated with
several metabolic disorders such as obesity, dyslipidemia, and type 2 diabetes (3). It is estimated
that 70–80% of obese or diabetic subjects have NAFLD, with a NASH prevalence of 10–20%.
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Despite the clinical importance of NAFLD/NASH, therapeutic
drugs against these diseases have not yet been developed.
However, numerous studies suggest that NASH develops by
multiple intracellular/extracellular events in different liver cell
types such as hepatocytes, hepatic stellate cells (HSCs), Kupffer
cells (resident macrophages in the liver), and infiltrating
macrophages (4) and by inter-organ crosstalk between the liver
and other tissues including adipose tissue or the intestine (5, 6).
This “multiple-parallel hit” model has recently been considered
as a more adequate hypothesis to understand the pathogenesis
of NASH than the “two-hit” model in which hepatic steatosis,
the “first hit,” increases susceptibility to NASH caused by a
“second hit” such as oxidative stress and inflammatory cytokines
(7). Here, we briefly highlight molecular mechanisms of the
pathogenesis of NASH, focusing on recent findings supporting
the “multiple-parallel hit” hypothesis. We also describe potential
therapeutic strategies based on hormones for treatment of NASH.
“MULTIPLE-PARALLEL HIT”
PATHOGENESIS OF NASH
Hepatocytes, Kupffer cells/infiltrating macrophages, and HSCs
play key roles in hepatic steatosis, inflammation, and fibrosis,
respectively. In this section, we discuss intracellular events in
individual cells and intercellular crosstalk between different cell
types within the liver in the pathogenesis of NASH, focusing
on recent advances in the potential role of hepatocytes. We
also briefly describe the importance of the adipose tissue-liver
axis and intestine-liver axis in the pathogenesis of NASH,
emphasizing the most recent findings (Figure 1).
Hepatic Intracellular and Intercellular
Crosstalk and NASH
Hepatocyte Lipid Accumulation
Hepatic steatosis develops by interactions among genetic,
metabolic, and environmental factors (8). Sedentary lifestyle
and excess caloric or inappropriate intake (high glucose, high
fructose, high fat, or high cholesterol diet) are well-known
environmental factors associated with hepatic steatosis and
NAFLD/NASH. Excess dietary glucose or fructose enters the liver
through the bloodstream after uptake in the small intestine and is
subsequently utilized for the production of hepatic triacylglycerol
(TG) via de novo fatty acid synthesis, as well as being a source
for hepatic glycogen storage. Dietary fatty acids absorbed in
the small intestine also contribute to hepatic TG formation by
two different pathways. In the first, free short-chain fatty acids
transported into the blood from the small intestine are taken up
by the liver via fatty acid transporter [cluster of differentiation
36 (CD36), fatty acid transporter protein (FATP)] together with
free fatty acid (FFA) “spillover” generated from lipoprotein
lipase (LPL)-mediated chylomicron hydrolysis. In the second
pathway, chylomicron TGs containing middle/long-chain fatty
acids are hydrolyzed by LPL in peripheral tissues such as skeletal
muscle and adipose tissue and consequently become chylomicron
remnants, which are taken up by the liver through their receptors
[low density lipoprotein receptor (LDLR) and LDL receptor-
related protein (LRP)].
In addition to environmental factors, metabolic factors
such as insulin resistance, obesity, and dyslipidemia increase
susceptibility to hepatic steatosis and NAFLD/NASH (9, 10). In
particular, insulin resistance in adipose tissue impairs the ability
of insulin to suppress lipolysis; consequently, FFAs released from
adipose tissue are transported into the liver. FFAs from adipose
tissue contribute to∼60% of hepatic lipid accumulation together
with FFA “spillover” (11). Hyperinsulinemia or hyperglycemia, a
key feature of insulin resistance, also increases hepatic de novo
fatty acid synthesis via upregulation of SREBP1 and ChREBP,
impairs hepatic β-oxidation, and enhances CD36-mediated
fatty acid uptake, thereby contributing to the development
of hepatic steatosis (12, 13). Genome-wide association studies
suggest that variation in several genes [e.g., PNPLA3 (patatin-
like phospholipase domain-containing protein 3), TM6SP2
(transmembrane 6 superfamily member 2), and FADS (fatty acid
desaturase)] related to hepatic lipid metabolism are associated
with increased hepatic steatosis in human NAFLD subjects
(14–16). A more detailed discussion regarding the contribution
of genetic (or epigenetic) factors to the pathogenesis of NASH
has been recently reviewed elsewhere (17). Thus, various risk
factors contribute to the development of hepatic steatosis and
NALFD/NASH by affecting hepatic lipid metabolism through
multiple pathways (Figure 1).
Hepatocyte Oxidative Stress, Lipotoxicity, and Cell
Death
Excessive lipid accumulation in the liver causes hepatocellular
lipotoxicity via cellular and organelle oxidative stresses
including endoplasmic reticulum (ER) stress and mitochondrial
dysfunction, eventually leading to hepatocyte cell death
(Figure 1) (18, 19). In particular, ER stress is implicated in
the development and progression of NAFLD (20, 21). When
cells are exposed in ER stress, the integrated stress signal
mediated by three ER stress sensors (PERK, IRE1α, and ATF6)
triggers unfolded protein response (UPR), which serves as
a compensatory mechanism to maintain ER homeostasis.
However, prolonged or excessive lipotoxic ER stress overwhelms
the capacity of UPR and induces hepatic cell death via two main
pathways (a mitochondria-dependent intrinsic pathway and
a death receptor-mediated extrinsic pathway) (22). Moreover,
chronic ER stress increases the production of reactive oxygen
species (ROS) and activates the NF-κB or c-Jun N-terminal
kinase (JNK) pathway, leading to hepatic inflammation (21). In
addition, chronic ER stress results in hepatic lipid accumulation
via activation of de novo fatty acid synthesis in a manner
dependent on ER stress-sensing pathways (23), suggesting that
a vicious cycle between ER stress and hepatic steatosis may
promote the development and progression of NAFLD/NASH.
The roles of saturated fatty acids and other lipid metabolites
[lysophosphatidylcholine (LPC), ceramide, and free cholesterol]
as potential mediators of hepatocellular lipotoxicity in
NAFLD/NASH have recently emerged (6, 19). Palmitic
acid, the most abundant long-chain saturated fatty acid
in vivo, has been reported to trigger oxidative stress and
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FIGURE 1 | The “mutiple-parallel hit” model in the pathogenesis of NASH. Three factors (environmental, metabolic and genetic factors) contribute to the development
and progression of NASH by affecting diverse organs such as the liver, the intestine, and adipose tissue. In particular, excess caloric or inappropriate intake
(environmental factor) increases toxic free fatty acid (FFA) and lipid metabolites (LPC, cholesterol and ceramide) in hepatocytes, leading to hepatic steatosis and
hepatocyte sublethal/lethal injuries. Subsequently, hepatocyte-derived factors (such as cytokines/chemokines, DAMPs and extracellular vesicles) stimulate
inflammatory response in Kupffer cell and fibrotic response in HSC, which leads to the development of inflammation and fibrosis in the liver. FFA and lipid metabolites
derived from diets or synthesized de novo also activates Kupffer cell and HSC. In addition, insulin resistance and obesity (metabolic factor) influence organ-crosstalk
between the intestine/adipose tissue and the liver, contributing to the development and progression of NASH.
ER/lysosomal/mitochondrial stresses, causing lipotoxicity-
related cell death (24–26). LPC and ceramide have been
also reported to act as lipid intermediates mediating the
effect of palmitic acid on hepatocellular lipotoxicity (27).
In particular, LPC generated from palmitic acid triggers
mitochondria-dependent apoptotic machinery via activation
of the G-protein-coupled receptor Galpha(i)-JNK pathway
(27) or of the CCAAT/enhancer binding homologous protein
(CHOP)/JNK pathway (28). Ceramide synthesized via a de
novo pathway from palmitic acid also causes mitochondrial
dysfunction (such as impairment of mitochondrial respiratory
chain and increase of mitochondrial membrane permeability),
leading to hepatocyte cell death (29). In addition, ceramide
generated from tumor necrosis factor alpha (TNFα)-induced
activation of the acid sphingomyelinase (ASMase) pathway
contributes to hepatocyte apoptosis (30). Another lipid
metabolite, free cholesterol, can also induce hepatocyte
necrosis/apoptosis by depleting mitochondrial glutathione (31)
and can induce hepatocyte pyroptosis/necrosis by generating
cholesterol crystals within lipid droplets (32). Importantly,
concentrations of saturated fatty acid (e.g., palmitic acid),
ceramide, LPC, or free cholesterol are increased in the livers
of human subjects with NASH (27, 33, 34) and of animals
with NASH (35), suggesting that free saturated fatty acids and
other lipid metabolites as mentioned above contribute to the
development and progression of NASH. Numerous studies
suggest that therapeutic approaches to inhibit hepatic lipid
accumulation, lipid-induced oxidative stress, and lipotoxicity-
mediated cell death are promising strategies for treatment
of NAFLD/NASH (36, 37). Phase 1, 2a, 2b, and 3 trials are
being undertaken to test peroxisome proliferator activated
receptor alpha/delta (PPARα/δ) activator (Elafibranor/GFT505;
Clinical Trials NCT02704403), liver X receptor alpha (LXRα)
inhibitor (Oltipraz; NCT02068339), acetyl-CoA carboxylase
(ACC) inhibitors (GS-0976; NCT02856555 and PF-05221304;
NCT03248882), stearoyl-CoA desaturase 1 (SCD1) inhibitor
(Aramchol; NCT02279524), diacylglycerol acyltransferase 1
(DGAT1) inhibitor (Pradigastat/LCQ908; NCT01811472), and
DGAT2 inhibitor (PF-06865571; NCT03513588) as targeting
strategies to reduce hepatic steatosis in NASH patients via
enhancement of β-oxidation or inhibition of fatty acid/TG
synthesis. Natural antioxidants such as vitamin E and resveratrol
have been used (or are being investigated) as therapeutic
compounds to attenuate oxidative stress (36, 38). Caspase
inhibitor (Emricasan/IDN-6556; NCT02686762) and apoptosis
signaling kinase-1 (ASK-1) inhibitor (Selonsertib/GS-4997;
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NCT03053050), which target hepatic cell death, are also
being evaluated in phase 2b and 3 studies of NASH patients,
respectively.
In particular, ASK1 inhibitor can reduce hepatic steatosis,
inflammation, and fibrosis (39, 40). In the unstimulated state,
inactive ASK1 forms a high-molecular protein complex through
homotypic interaction between two adjacent carboxy-terminal
coiled-coil domains and through binding of its N-terminal region
to thioredoxin (TRX). In an oxidative stressed state, ASK1
dissociated from TRX is homo-oligomerized in association with
TNF receptor-associated factor (TRAF) and is subsequently auto-
phosphorylated on threonine residue Thr838, which ultimately
leads to the formation of active ASK1 signalosome. Then,
this complex phosphorylates and activates p38 and JNK,
resulting in increase of hepatocyte injury via the BAX-caspase
pathway, impairment of hepatic insulin resistance via Ser307
phosphorylation of insulin receptor substrate, increase of
hepatic inflammation via pro-inflammatory cytokine/chemokine
production, and increase of hepatic fibrosis via collagen
production (39, 40). Recent emerging evidence suggests that
several ASK1-interacting proteins such as Dickkopf-3 (DKK3),
CASP8 and FADD-like apoptosis regulator (CFLAR, known as
cFlip), and TNFα-induced protein 3 (TNFAIP3, known as A20)
represent attractive therapeutic targets for the prevention and
treatment of NAFLD/NASH (41–43). Further understanding
of molecular mechanisms underlying the regulation of ASK1
activity will provide opportunities to identify novel therapeutic
targets and to develop promising therapeutic compounds for
treatment of NAFLD/NASH.
Hepatocyte-Derived Secretory Cytokines,
Damage-Associated Molecular Patterns (DAMPs),
and Extracellular Vesicles
Several studies suggest that hepatocyte-derived factors
(or molecules) can act on non-parenchymal cells such as Kupffer
cells and HSCs, which can in turn contribute to the progression
of NASH (Figure 1) (44–46). In response to various stimuli such
as excessive lipids and lipopolysaccharide (LPS), hepatocytes can
directly produce chemokines [chemokine (C-C motif) ligand
2 (CCL2)] and pro-inflammatory cytokines (TNFα, IL-6 and
IL-1β), although the amount of chemokines/cytokines released
from hepatocytes is lower compared to that released from non-
parenchymal cells. Subsequently, increased chemokine/cytokine
production results in infiltration of macrophages into the liver
and activation of Kupffer cells/HSCs (44, 46). In addition,
sublethal or lethal hepatocellular injuries (apoptosis, necrosis,
necroptosis, or pyroptosis) trigger signals for NASH promotion
through releases of inflammatory cytokines, damage-associated
molecular patterns (DAMPs) such as high mobility group
box 1(HMGB1), ATP, uric acid, or mitochondrial DNA, and
extracellular vesicles (18, 44, 47). DAMPs can cause hepatic
inflammation and fibrosis by activating Kupffer cells and HSCs
via paracrine or endocrine actions (44, 47).
It has been reported that circulating levels of extracellular
vesicles such as microvesicles (microparticles) and exosomes
are increased in NASH mouse models (48, 49) and patients
with NASH (50). Extracellular vesicles released from hepatocytes
treated with lipotoxic fatty acids can act as messenger signals
mediating intercellular communication between hepatocytes and
non-parenchymal cells, which contributes to aggravation of
inflammation and fibrosis in NASH (48, 49, 51). For example,
saturated fatty acids stimulate the release of extracellular
vesicles including vanin-1, a surface cargo protein found on
hepatocytes, leading to increases in chemotaxis and migration
of endothelial cells (48). Consequently, enhanced angiogenesis
promotes recruitment of inflammatory cells and fibrogenesis
of HSCs, contributing to the progression of NASH. In
addition, fatty acid-induced release of exosomes containing
microRNAs (miR-128-3p) contributes to the activation of
HSCs in fibrosis (49). Palmitic acid and LPC also induce
the release of extracellular vesicles from hepatocytes via
the death receptor 5 (DR5) signaling pathway or rho-
associated coiled-coil-containing protein kinase 1 (ROCK1)
(51). In this process, TRAIL-bearing extracellular vesicles
activate inflammatory responses in macrophages via the DR5
signaling pathway in a receptor-interacting serine/threonine-
protein kinase 1 (RIPK1)-dependent manner (51). Furthermore,
mass spectrometry analysis demonstrated the presence of many
DAMPs in extracellular vesicles released from hepatocytes (52).
All these findings suggest that extracellular vesicles play key roles
in intercellular communication between different cell types in the
liver and in the development and progression of NASH. Due to
the importance of extracellular vesicles in NASH pathogenesis,
strategies to block the release of extracellular vesicles and to
inhibit specific molecules (or cargos) within extracellular vesicles
have been considered as therapeutic interventions for NASH.
Kupffer Cells/Infiltrating Macrophages, Inflammation,
and NASH
In addition to hepatocyte-derived factors, lipotoxic fatty acids
such as palmitic acid and ceramide can activate Kupffer cells
and subsequently promote the production of pro-inflammatory
cytokines (TNFα and IL-6) (Figure 1) (53). Kupffer cells also
secrete several chemokines such as CCL2, chemokine (C-X-C
motif) ligand 16 (CXCL16), and CXCL1/2/8 to recruit peripheral
macrophages, natural killer T cells, and neutrophils, respectively
(Figure 1) (54–56). Consequently, Kupffer cells and recruited
innate immune cells can coordinately aggravate inflammation
in the liver. Moreover, several cytokines such as TGFβ, lectin
galactose binding soluble 3 (LGALS3, known as Galectin-
3), platelet-derived growth factor (PDGF), and TNFα/IL-1β
produced from Kupffer cells/infiltrating macrophages are able to
activate quiescent HSCs and increase proliferation or survival
of HSCs (Figure 1) (57–60). In addition, palmitic acid-induced
TNFα and IL-1β in infiltrating macrophages can cause lipid
accumulation and insulin resistance in hepatocytes (61).
Inflammasome is a cytoplasmic multiprotein complex
that is activated by two distinct signals: the first signal for
upregulation of inflammasome-related genes [pro-IL-1β, NLR
family pyrin domain containing 3 (NLRP3), and Caspase 1]
and a second signal for functional inflammasome assembly
and activation of Caspase 1 (62). Inflammasome-mediated
IL-1β secretion is initiated by activation of toll-like receptors
(TLR) as a priming signal and stimulated by diverse second
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signals such as DAMPs, pathogen-associated molecular
patterns (PAMPs) (e.g., pore-forming toxin), and toxic lipids
(e.g., palmitic acids and cholesterol crystals) (63). NLRP3
inflammasome-dependent IL-1β secretion from activated
Kupffer cells/infiltrating macrophages and hepatocytes plays
a crucial role in progression of NAFLD/NASH (64, 65). Mice
with global overexpression of mutant NLRP3 (constitutive
active) showed severe hepatocyte pyroptotic cell death and
severe hepatic inflammation/fibrosis, while myeloid cell (Kupffer
cells)-specific mutant NLRP3-overexpressing mice exhibited
mild hepatic inflammation/fibrosis in the absence of hepatocyte
pyroptotsis (64), suggesting that both Kupffer cells and
hepatocytes are important in NLRP3 inflammation-mediated
liver injury. In parallel, NLRP3 knockout mice showed improved
hepatic injury, inflammation, and fibrosis in the liver after a
choline-deficient amino acid-defined (CDAA) diet feeding (65).
Furthermore, treatment with MCC950 (CP-456773), a small
molecule NLRP3 inhibitor, attenuates liver inflammation and
fibrosis in mice fed a methionine-choline-deficient (MCD) diet
(66). IL-1β knockout mice also displayed reduced steatohepatitis
and hepatic fibrosis after an atherogenic cholesterol-rich
diet feeding (67). In contrast, IL-1β receptor antagonist (IL-
1Ra) knockout mice showed aggravated hepatic steatosis,
inflammation, and fibrosis after the same diet feeding (68).
All these results suggest that inhibition of NLRP3 or IL-1β
could be an attractive therapeutic strategy for treatment of
NALFD/NASH.
Due to the crucial role of Kupffer cell/infiltrating
macrophages-derived cytokines/chemokines in steatosis,
inflammation, and fibrosis, functional inhibition of these
secretory proteins is considered as a promising therapeutic
approach for treatment of NASH. An orally available drug
capable of inhibiting recruitment of monocyte/macrophage
and activation of HSCs, dual chemokine (C-C motif) receptor
2 (CCR2)/CCR5 antagonist (Cenicriviroc: NCT03028740)
is currently being investigated in a phase 3 clinical trial of
human NASH patients with liver fibrosis. An oral inhibitor
(BI1467335/PXS-4728A; NCT03166735) of amine oxidase
copper-containing 3 (AOC3) is being evaluated in a phase 2a
NASH study as an anti-inflammatory compound to block the
recruitment of immune cells in the liver. Galectin-3, a Kupffer
cell/macrophage-derived lectin, is required for TGFβ-mediated
activation of HSCs (59), and an inhibitor of Galectin 3 (GR-MD-
02; NCT02462967) is also being evaluated as an anti-fibrotic
drug in a phase 2b trial in NASH patients.
HSCs, Fibrosis, and NASH
HSCs, the major source of type I collagen in the liver, play
a crucial role in NASH-related fibrosis (69). Hepatocyte-
derived factors (cytokines, DAMPs, or extracellular vesicles)
and Kupffer/macrophage-released cytokines/chemokines
trigger signaling cascades to transform “quiescent” HSCs into
“activated” HSCs (myofibroblast-like cells) (69). Consequently,
activated HSCs increase the secretion of collagen and other
extracellular matrix proteins, leading to fibrotic scarring and
ultimately chronic fibrosis in the liver (69). Thus, one of
the potential strategies to inhibit NASH-related fibrosis is to
suppress accumulation of extracellular matrix proteins including
collagen or to directly inhibit HSC activation. Lysyl oxidase-like
2 (LOXL2), an enzyme promoting collagen cross-linking, is
upregulated in the livers of animals with fibrosis (70) and of
diabetic patients with NAFLD (71) and is essential in hepatic
fibrogenesis (72). Phase 2b clinical studies in NASH patients
using an antibody against LOXL2 (Simtuzumab/GS-6624;
NCT01672866 and NCT01672879) were recently terminated.
Simtuzumab had no effect on hepatic fibrosis in NASH patients
with bridging fibrosis or cirrhosis (73). Heat shock protein 47
(HSP47) is a molecular chaperone which plays a crucial role
in the maturation and secretion of collagen. While vitamin
A-coupled lipid nanoparticle (BMS-986263/ND-LO2-s0201)
containing siRNA against HSP47 is being investigated in
preclinical stage for treatment of NASH, efficacy of BMS-986263
in human fibrosis patients (NCT02227459) and human cirrhosis
patients (NCT03420768) are being evaluated in phase 1 and 2
clinical trials, respectively.
Inter-organ Crosstalk and NASH
Recent knowledge regarding the roles and contributions of
adipose tissue and intestine in the pathogenesis of NASH have
been extensively highlighted in previous reviews (5, 6). Here, we
briefly describe the relationships between the adipose tissue-liver
axis or intestine-liver axis and NASH.
Adipose Tissue-Liver Axis and NASH
Obesity-associated insulin resistance in adipose tissue
contributes to the development and progression of hepatic
steatosis and NASH (5). As mentioned previously, impaired
suppression of insulin-mediated lipolysis in white adipose tissue
(WAT) leads to hepatic steatosis through increased fatty acid
uptake of hepatocytes (Figure 1). In addition, inflammation
in WAT systemically affects hepatic inflammation (74). Lean
mice transplanted with visceral adipose tissue from obese mice
exhibited elevated infiltration of neutrophils and macrophages
in the liver and ultimately suffered from aggravated liver damage
after NASH diet feeding (74). However, transplantation of
visceral fat from obese mice with depletion of adipose tissue
macrophage (ATM) by treatment with clodronate liposomes did
not cause hepatic inflammation in lean mice (74), suggesting that
ATM directly contributes to hepatic inflammation and NASH
progression. Furthermore, adipokines (such as adiponectin
and leptin) secreted from WAT have reported to affect
lipid accumulation, inflammation, and fibrosis in the liver
(Figure 1) (75).
In addition to the role of WAT, BAT (brown adipose tissue)
is associated with the development and progression of NAFLD.
A couple of previous papers suggest that transplantation of
BAT alleviates hepatic steatosis in HFD-fed obese mice and
leptin-deficient ob/ob mice (76, 77). Conversely, treatment with
propranolol, a β-adrenergic receptor antagonist, worsens liver
injury in mice fed a half-methionine and choline-deficient
diet supplemented with ethionine (HMCDE) due to increased
hepatocyte cell death (78). Furthermore, a recent paper suggests
that thermoneutral housing exacerbates HFD-driven NAFLD in
mice, which is related to reduced activation of BAT, although
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additional events (augmented intestinal permeability, dysbiosis
of themicrobiome, and altered immune responsiveness caused by
decreased norepinephrine/corticosterone) could also contribute
to these phenotypes (79). Despite the presence of severe steatosis
and inflammation in HFD-fed mice housed at a thermoneutral
temperature, hepatic fibrosis did not develop in these mice (79).
Thus, it will be interesting to investigate whether activation
of thermogenic adipocytes ameliorates the development and
progression of NASH in mice fed NASH diets such as MCD diet,
high-fat/high-cholesterol diet, or high-fat/high-fructose diet.
Intestine-Liver Axis and NASH
Growing evidence suggests that the intestine-liver axis plays
a crucial role in the maintenance of metabolic homeostasis,
and that its impairment is an important causal factor in
the pathogenesis of diverse liver diseases such as obesity-
related steatosis, NAFLD/NASH, and liver cancer (80, 81).
Feeding of HFD or NASH diets causes impairment of intestinal
barriers, dysbiosis of the microbiota, and alterations of intestinal
immunity, leading to increased translocation of bacteria or
bacterial products into the systemic circulation (82, 83).
Consequently, bacteria or bacterial products are able to reach
the liver through the portal vein. In the liver, conserved
motifs/structures of bacteria and bacterial products (PAMPs) are
recognized by pathogen recognition receptors (PPRs) of various
cell types (hepatocytes, Kupffer cells/infiltrating macrophages,
and HSCs). In particular, PAMPs such as LPS, peptidoglycan,
and bacterial DNA stimulate multiple signaling cascades via
interactions with PAMP-specific TLRs and NOD-like receptors
(NLRs), leading to hepatic steatosis, inflammation, and fibrosis
in the liver (Figure 1) (6, 84).
Emerging evidence suggests that lipid intermediates derived
from the intestine trigger the development of NAFLD/NASH
and insulin resistance (85, 86). In mice fed diets supplemented
with palmitic acid or palm oils, concentrations of ceramide were
increased in the intestine and serum/plasma (87). Ceramide
derived from the intestines of mice fed HFD systemically causes
ER/mitochondrial stresses and increases fatty acid synthesis in
hepatocytes, which leads to hepatic lipid accumulation, hepatic
cell death, and inflammation (Figure 1) (85, 86). Intriguingly,
these phenotypes are attenuated in intestine-specific hypoxia-
inducible factor 2α (HIF2α)- or farnesoid X receptor (FXR)-
knockout mice which showed decreased intestinal ceramide
level due to reduced expression of HIF2α- or FXR-target genes
involved in ceramide synthesis (85, 86). Furthermore, intestinal
ceramide production and hepatic steatosis are attenuated in
HFD-fedmice treated with antibiotics (85), suggesting that HFD-
induced alterations of the microbiota contribute to increased
intestinal ceramide production and hepatic lipid accumulation.
In particular, taurocholic acid (TCA) and tauro-β-muricholic
acid (T-β-MCA) produced from the liver competitively act as
agonist and antagonist for FXR signaling in intestinal epithelial
cells, respectively (85). In mice fed HFD, T-β-MCA is converted
to MCA by bile salt hydrolase (BSH), a microbial enzyme,
which results in aggravated hepatic steatosis and hepatic injury
due to increased intestinal ceramide production via activation
of TCA-mediated agonistic action for FXR and inhibition of
T-β-MCA-mediated antagonistic action (85). In HFD-fed mice
treated with antibiotics, however, accumulated T-β-MCA inhibits
intestinal FXR signaling and subsequently suppresses intestinal
ceramide synthesis, leading to improvements in hepatic steatosis
and hepatic injury (85). In addition, hormones derived from
the intestine influence the development and progression of
NAFLD/NASH (88), which will be discussed in next section. In
view of the importance of impaired intestinal barrier-induced
penetration of microbial products and microbial dysbiosis-
induced changes of intestinal signaling in the pathogenesis of
NAFLD/NASH, therapeuticmodulation of the intestine-liver axis
represents an attractive strategy for treatment of NAFLD/NASH.
A phase 2a clinical study using IMM-124E (composed of anti-
LPS antibody and glycosphingolipid adjuvants) is currently
underway in human NASH patients (NCT02316717). Further
understanding of intestine-liver interactions will help identify
novel therapeutic targets and molecules to prevent and treat
NAFLD/NASH.
HORMONE-BASED THERAPEUTIC
APPROACHES FOR TREATMENT OF NASH
Based on the “multiple-parallel hit” model of the pathogenesis
of NASH, therapeutic approaches such as reduction of steatosis,
blockade of hepatic cell death, suppression of hepatic immune
cells, and inhibition of fibrogenic action of HSCs are considered
as attractive strategies for treatment of NASH. Since hormones
systemically influence diverse tissues (or cell types) in the body,
they can have effects on multiple steps in the pathogenesis of
NASH. Thus, hormone-based therapy is an attractive strategy for
treatment of NASH. In this section, we briefly review current
hormone-based NASH therapies.
Fibroblast Growth Factor 19
(FGF19)-Based NASH Therapy
FGF19 (FGF15 in rodents) is a postprandial endocrine
hormone that is produced in the intestine by bile acid-
induced FXR activation (89), and that plays a key role in the
regulation of bile acid and lipid metabolism in the liver (89).
FGF19 also inhibits gluconeogenesis and stimulates hepatic
glycogen and protein synthesis via insulin-independent action
(90). In addition to its physiological effects, therapeutic
administration of FGF19 or genetic overexpression of
FGF19 also have pharmacological effects such as decreased
hepatosteatosis/adiposity and improved insulin sensitivity
via enhancement of β-oxidation/thermogenesis, inhibition of
lipogenesis, or amelioration of lipotoxicity-induced ER stress
(91–93). In contrast, HFD-fed FGF15 knockout mice showed
increased adiposity or exacerbated ER stress and hepatosteatosis
(93). Recent emerging studies suggest that FGF19 ameliorates
muscle wasting via direct action on skeletal muscle (94) and
corrects type 1 diabetes via inhibition of the hypothalamic–
pituitary–adrenal axis (95). Intriguingly, circulating FGF19 level
is decreased in human NAFLD/NASH subjects, and hepatic
response to FGF19 is impaired in human NAFLD subjects with
insulin resistance (96, 97). Therapeutic administration of an
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engineered FGF19 (NGM282/M70, a nontumorigenic FGF19
variant) eliminates lipotoxicity and bile acid toxicity, leading to
improvements of steatohepatitis and fibrosis in a NASH mouse
model (98). However, endogenous FGF15 deletion had no effect
on steatosis, inflammation, or fibrosis in mice fed HFD for
6 months (99). In a phase 2a clinical study (NCT02443116),
treatment of human NASH patients with NGM282 resulted
in reduced hepatic steatosis and decreased markers of hepatic
inflammation/fibrosis with acceptable safety (100).
FGF21-Based NASH Therapy
FGF21 is expressed as an endocrine hormone predominantly
in the liver and other metabolic tissues such as adipose
tissue, muscle, and pancreas. FGF21 plays physiologically
important roles in the regulation of glucose/lipid metabolism
and maintenance of energy balance in response to changes
in nutritional status such as starvation (101, 102) and
environmental stimuli such as cold exposure or exercise (103,
104). FGF21 can exert beneficial effects on obesity and related
metabolic diseases (105, 106). Pharmacological treatment with
FGF21 or overexpression of FGF21 improves diet-induced
obesity and insulin resistance by enhancing insulin-mediated
glucose uptake and β-oxidation/thermogenesis (105, 106).
Furthermore, FGF21 ameliorates obesity-induced ER stress,
increased serum levels of liver enzymes, and insulin resistance
(107). Emerging evidence suggests that FGF21 is also implicated
in the pathogenesis and treatment of NASH (108, 109). FGF21
is increased in the livers of NASH animal models (108) and
of human patients with NASH (109). Therapeutic treatment
with FGF21 or overexpression of FGF21 causes improvements
of MCD diet-induced steatosis, inflammation, and fibrosis in
mice by reducing hepatic lipotoxicity and increasing β-oxidation
(108). Moreover, treatment with FGF21 suppresses PDGF-
induced activation of HSCs in vitro (110), implying that direct
anti-fibrogenic action of FGF21 in HSCs may contribute to
FGF21-induced improvement of fibrosis in vivo. In line with
preclinical studies, a recent phase 2a clinical study using a
pegylated analog of FGF21 (PEG-FGF21, BMS-986036) suggests
reduction of steatosis and improvement of markers of fibrosis
and liver injury in human NASH patients (111). Phase 2b
clinical studies (NCT03486899 and NCT03486912) to evaluate
the safety and efficacy of BMS-986036 in human NASH
patients with severe stage 3 fibrosis or cirrhosis were recently
started.
Glucagon-Like Peptide 1 (GLP-1)-Based
NASH Therapy
GLP-1 is a proglucagon-derived hormone that is secreted
from the intestine in response to changes in nutrients (112).
GLP-1 plays a crucial role in the regulation of glucose
metabolism by enhancing insulin release, suppressing glucagon
secretion, and inhibiting gastric emptying (112). Furthermore,
pharmacological treatment with GLP-1 leads to improvements
of diet-induced obesity and insulin resistance by suppression of
food intake and enhancement of thermogenesis (113, 114). Seven
synthetic GLP-1 receptor agonists (exenatide, exenatide long-
acting release, liraglutide, albiglutide, dulaglutide, lixisenatide,
and semaglutide) are approved and available for treatment of
type 2 diabetes. Intriguingly, GLP-1 analogs also ameliorate
not only hepatic steatosis, but also hepatic inflammation and
fibrosis in mice (115). Furthermore, in a phase 2 clinical study
(NCT01237119) for efficacy of liraglutide in human NASH
patients, patients receiving liraglutide for 48 weeks showed
significant reductions of hepatic ballooning, steatosis, and serum
alanine aminotransferase (ALT) level compared to patients
who received placebo (116). Liraglutide-induced reduction of
hepatic lipid accumulation is probably due to decreased hepatic
de novo fatty acid synthesis (117). A phase 2 clinical study
using semaglutide in human NASH patients (NCT02970942) is
currently underway.
In line with the therapeutic effect of GLP-1, pharmacological
treatment with sitagliptin or linagliptin, inhibitors of
dipeptidylpeptidase 4 (DPP4), an enzyme that degrades GLP-1,
improves hepatic steatosis, inflammation, and fibrosis in NASH
mouse models (118, 119). Furthermore, vildagliptin, another
DPP4 inhibitor, ameliorates serum liver enzyme levels and
hepatic steatosis in human NAFLD patients with dyslipidemia
(120). In contrast, sitagliptin treatment for 24 weeks had no
beneficial effects on serum liver enzyme levels, fatty liver, or
fibrosis in human NASH or NAFLD patients (NCT01260246
and NCT01963845) (121, 122). Further large-scale studies are
needed to evaluate the efficacy and clinical importance of DDP4
inhibitor for treatment of NAFLD/NASH.
Glucagon/GLP-1 receptor dual agonists and
glucagon/glucose-dependent insulinotropic polypeptide
(GIP)/GLP-1 receptor triple agonists are attractive therapeutic
agents to treat NAFLD/NASH as well as obesity-related
diabetes (123, 124). Some preclinical studies have shown
improvement of obesity-related metabolic deterioration in
mice treated with glucagon/GLP-1 receptor dual agonist
(125) or glucagon/GIP/GLP-1 receptor triple agonist (126).
Pharmacological treatment with a pegylated analog of
oxyntomodulin (PEG-OXM, G49), a natural agonist of the
glucagon/GLP-1 receptor, improves steatohepatitis in MCD
diet-fed mice, probably due to reductions of ER/mitochondrial
stresses and hepatocyte apoptosis (127). Treatment with
glucagon/GIP/GLP-1 receptor triple agonists also leads to
significant improvement of steatohepatitis in female mice
fed high-fat/high-sucrose diets and also in male mice,
albeit to a lesser extent (128). While several phase 1 or 2
clinical studies using glucagon/GLP-1 receptor dual agonists
and glucagon/GIP/GLP-1 receptor triple agonists are being
conducted in human obese diabetic patients (123, 124), clinical
studies using glucagon/GLP-1 receptor dual agonist (SAR425899;
NCT03437720) and glucagon/GIP/GLP-1 receptor triple agonist
(HM15211) for NASH patients have recently been registered.
Growth Differentiation Factor 15
(GDF15)-Based NASH Therapy
GDF15, an endocrine hormone belonging to the TGFβ
superfamily, is ubiquitously expressed in various tissues, with the
highest levels in the liver, placenta, and macrophages (129–131).
Numerous studies suggest that GDF15 is induced by diverse
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TABLE 1 | Pharmacological agents under development for treatment of NAFLD/NASH.
Drugs Target of Action Company Highest developmental stage/
clinical trial identifier
BILE ACID (BA) METABOLISM-RELATED AGENTS (MONOTHERAPY)
Obeticholic acid/OCA
(INT-747)
FXR agonist Intercept Pharmaceuticals Phase 3
/NCT03439254, NCT02548351
Px-104 FXR agonist Phenex Pharmaceuticals Phase 2a (discontinued)
/NCT01999101
Tropifexor (LJN452) non-BA FXR agonist Novartis Phase 2a/NCT02855164
LMB763 non-BA FXR agonist Novartis Phase 2a/NCT02913105
EDP-305 non-BA FXR agonist Enanta Pharmaceuticals Phase 2a/NCT03421431
GS-9674 FXR agonist Gilead Sciences Phase 2/NCT02854605
INT-767 FXR/TGR5 dual agonist Intercept Pharmaceuticals Pre-clinical phase
Volixibat (SHP626) IBAT inhibitor Shire Pharmaceuticals Phase 2/NCT02787304
LIPID METABOLISM-RELATED AGENTS (MONOTHERAPY)
Elafibranor (GFT505) PPARα/δ activator Genfit Phase 3/NCT02704403
Saroglitazar PPARα/γ activator Zydus Discovery Phase 2/NCT03061721
IVA337 PPARα/δ/γ activator Inventiva Pharma Phase 2/NCT03008070
Oltipraz LXRα inhibitor PharmaKing Phase 3/NCT02068339
GS-0976 ACC inhibitor Gilead Sciences Phase 2a/NCT02856555
PF-05221304 ACC inhibitor Pfizer Phase 2a /NCT03248882
Gemcabene ACC/ApoC-III inhibitor Gemphire Therapeutics
/Pfizer
Phase 2a/NCT03436420
Aramchol SCD1 inhibitor Galmed Pharmaceuticals Phase 2b/NCT02279524
Pradigastat (LCQ908) DGAT1 inhibitor Novartis Phase 2a/NCT01811472
PF-06865571 DGAT2 inhibitor Pfizer Phase 1/NCT03513588
MGL-3196 TRβ receptor agonist Madrigal Pharmaceuticals Phase 2/NCT02912260
VK2809 TRβ receptor agonist Viking Therapeutics Phase 2a/NCT02927184
GLUCOSE/FRUCTOSE METABOLISM-RELATED AGENTS (MONOTHERAPY)
LIK066 SGLT1/2 inhibitor Novartis Phase 2a/NCT03205150
PF-06835919 KHK inhibitor Pfizer Phase 2a/NCT03256526
LIPOTOXIC STRESS AND CELL DEATH-RELATED AGENTS (MONOTHERAPY)
Emricasan (IDN-6556) Caspase inhibitor Conatus/Novartis Phase 2b/NCT02686762
Selonsertib (GS-4997) ASK-1 inhibitor Gilead Sciences Phase 3/NCT03053050
MITOCHONDRIAL METABOLISM-RELATED AGENT (MONOTHERAPY)
MSDC-0602 mTOT modulator
/MPC inhibitor
Cirius Therapeutics Phase 2b/NCT0278444
EXTRACELLULAR VESICLES-RELATED AGENT (MONOTHERAPY)
RG-125 (AZD4076) Anti-miR targeting
microRNA−103/107
Regulus/Astrazenenka Phase 1 (discontinued)
/NCT02612662
INFLAMMATION AND INFLAMMASOME-RELATED AGENTS (MONOTHERAPY)
MCC950 (CP-456773) NLRP3 inhibitor Pfizer Pre-clinical phase
Cenicriviroc CCR2/5 dual antagonist Allergan Phase 3/NCT03028740
BI1467335
(PXS-4728A)
AOC3 inhibitor Boehringer Ingelheim/
Pharmaxis
Phase 2a/NCT03166735
GRI-0621 Natural killer T cell inhibitor GRI Bio Phase 2a/NCT02949375
Tipelukast (MN-001) LT/PDE/5-LO inhibitor MediciNova Phase 2a/NCT02681055
Nalmafene (JKB-121) TLR4 antagonist TaiwanJ Pharmaceuticals Phase 2/NCT02442687
CF102 A3AR agonist Can-Fite Biopharma Phase 2/NCT02927314
DS102 (AF-102) 15-HEPE DS Biopharma/
Afimmune
Phase 2a/NCT02941549
FIBROSIS-RELATED AGENTS (MONOTHERAPY)
GR-MD-02 Galectin-3 inhibitor Galectin Therapeutics Phase 2b/NCT02462967
(Continued)
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TABLE 1 | Continued
Drugs Target of Action Company Highest developmental stage/
clinical trial identifier
Simtuzumab(GS-6624) LOXL2 inhibitor Gilead Sciences Phase 2b (discontinued)/NCT01672866,
NCT01672879
BMS-986263(ND-LO2-s0201) HSP47 siRNA Nitto Denko/BMS Pre-clinical phase
INTESTINE AND MICROBIOTA-RELATED AGENTS (MONOTHERAPY)
IMM-124E anti-LPS antibody and
glycosphingolipid adjuvants
Immuron Phase 2a/NCT02316717
Solithromycin Macrolide antibiotic Cempra Inc Phase 2/NCT02510599
INSULIN RESISTANCE-RELATED AGENTS (MONOTHERAPY)
RO5093151 11β-HSD1 inhibitor Hoffmann-La Roche Phase 1/NCT01277094.
NS-0200 Leucine/Metformin/Sildenafil NuSirt Biopharma Phase 2/NCT02546609
HORMONE-RELATED AGENTS (MONOTHERAPY)
NGM282 FGF19 analog NGM BIO Phase 2a/NCT02443116
BMS-986036
(PEG-FGF21)
FGF21 analog BMS Phase 2b
/NCT03486899, NCT03486912
Liraglutide GLP-1 receptor agonist Novo Nordisk Phase 2/NCT01237119
Semaglutide GLP-1 receptor agonist Novo Nordisk Phase 2/NCT02970942
Sitagliptin DPP4 inhibitor MSD Phase 2/NCT01963845
Not applicable /NCT01260246
Vildagliptin DPP4 inhibitor Novartis Not applicable
SAR425899 Glucagon/GLP-1 receptor
dual agonist
Sanofi-Aventis Phase 2/NCT03437720
G49 (PEG-OXM) Glucagon/GLP-1 receptor
dual agonist
MedImmune Pre-clinical phase
HM15211 Glucagon/GIP/GLP-1 receptor triple
agonist
Hanmi Pharmaceutical Phase 1/Clinical trial approval (April 2018)
NGM386, NGM395 GDF15 analogs NGM BIO Pre-clinical phase
YH25724 GLP-1/FGF21 dual agonist Yuhan Corporation Pre-clinical phase
COMBINED THERAPY
Tropifexor (LJN452) +
Cenicriviroc (CVC)
FXR agonist + CCR2/5 dual
antagonist
Novartis + Allergan Phase 2b/NCT03517540
Selonsertib (GS-4997)+
GS-0976 + GS-9674
ASK-1 inhibitor +
ACC inhibitor + FXR agonist
Gilead Sciences Phase 2/
NCT02781584, NCT03449446
*A3AR, A3 adenosine receptor; ACC, acetyl-CoA carboxylase; AOC3, amine oxidase copper-containing 3; ASK-1, apoptosis signaling kinase-1; CCR2/5, dual chemokine (C-C motif)
receptor 2/5; DGAT, diacylglycerol acyltransferase; DPP4, dipeptidylpeptidase 4; FGF, fibroblast growth factor; FXR, farnesoid X receptor; GDF15, growth differentiation factor 15; GIP,
glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; 15-HEPE, 15-hydroxyeicosapentaenoic acid; 11β-HSD1, 11-beta-hydroxysteroid dehydrogenase type
1; HSP47, heat shock protein 47; IBAT, ileal apical sodium-dependent bile acid transporter; KHK, ketohexokinase; LOXL2, lysyl oxidase-like 2; LPS, lipopolysaccharide; LT/PDE/5-LO,
leukotriene/phosphodiesterase/5-lipoxygenase; LXR, liver X receptor; NLRP3, NLR family pyrin domain- containing 3; MPC, mitochondrial pyruvate carrier; mTOT, mitochondrial target of
thiazolidinedione; PPAR, peroxisome proliferator activated receptor; SCD1, stearoyl-CoA desaturase 1; SGLT, sodium/glucose cotransporter; TGR5, takeda G protein-coupled receptor
5; TLR4, toll-like receptor 4; TR, thyroid hormone receptor.
stress stimuli such as fatty acids, ER/mitochondrial stressors,
and LPS (132–134), and that serum GDF15 level is increased
in human subjects with diseases such as cardiovascular disease,
chronic kidney disease, obesity, diabetes, and cancer (135, 136).
Intriguingly, recent emerging evidence suggests that GDF15
exerts beneficial effects on obesity-related insulin resistance in
mice and monkeys through the suppression of food intake
via GDNF family receptor α-like (GFRAL)-dependent anorexic
action (137–140). GDF15 also stimulates oxidative metabolism
in macrophages or metabolic tissues such as adipose tissue
and liver, leading to the improvement of insulin resistance and
hepatic steatosis in obese mice (133, 141). In addition to its
anti-obesity and anti-diabetic effects, GDF15 has been implicated
in the development and progression of NAFLD/NASH (142,
143). Serum GDF15 level is elevated in NASH animal models
(143) and in human subjects with NASH (142, 143). In two
dietary NASH models using MCD and amylin liver NASH
(AMLN) diets, GDF15 knockout mice showed deteriorated
steatohepatitis and fibrosis in the liver, while GDF15 transgenic
mice were resistant to diet-induced NASH phenotypes (143).
Furthermore, treatment with recombinant GDF15 ameliorates
lipid accumulation, inflammation, and fibrosis in mice caused
by alcohol feeding (144), suggesting that GDF15 is a promising
therapeutic candidate to treat alcoholic steatohepatitis (ASH) as
well as NASH. While preclinical studies using GDF15 analogs
have been conducted, clinical studies aimed at treating obesity-
related type 2 diabetes or NAFLD/NASH have yet to be
performed.
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DISCUSSION
NAFLD/NASH is a public health problem worldwide, but
there are no therapeutic drugs approved for its treatment.
Numerous preclinical animal models based on genetic or
dietary manipulation with relevance to human NAFLD/NASH
have been developed to explore the mechanisms underlying
the development of NAFLD/NASH and identify novel targets
for its treatment (145, 146). The studies conducted using
these models have made important steps forward in our
understanding of the pathogenesis of NASH and in the
discovery of potential therapeutic candidates. As discussed above,
sophisticated communication between parenchymal and non-
parenchymal cells in the liver or between the liver and other
organs contributes to the development and progression of
NAFLD/NASH (Figure 1). Thus, multiple components (hepatic
lipid accumulation, oxidative stress, ER/mitochondrial stress,
hepatocyte cell death, hepatocyte-released DAMPs/extracellular
vesicles, Kupffer cell activation, inflammatory cell recruiting,
HSC activation, insulin resistance, adipose tissue inflammation,
and microbiota dysbiosis) are attractive therapeutic targets to
treat NAFLD/NASH. In this review, we summarize preclinical or
clinical therapeutic efficacies of several pharmacological agents
targeting these multiple components of NASH. Pharmacological
agents under development for treatment of NAFLD/NASH
(including some candidates not discussed in this review) are
listed in Table 1. Given the value of a “multiple-parallel model”
in the pathogenesis of NASH, monotherapy with a single agent
targeting multiple components (e.g., BMS-986036/PEG-FGF21
for targeting insulin resistance, hepatic lipid accumulation,
oxidative stress, and ER stress) or combined therapy with agents
targeting a single component (e.g., ASK1 inhibitor [Selonsertib]
and ACC inhibitor [GS-0976]) will be efficacious therapeutic
approaches for treatment of NASH, in addition to monotherapy
with an agent targeting a single component. Thus, further
understanding of NASH pathogenesis and preclinical/clinical
studies to evaluate the efficacy of candidate agents will accelerate
novel therapeutic innovations for treatment of NAFLD/NASH
and related metabolic disorders.
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